← All trials
NCT06552234
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Sep 30, 2031
- Completion date
- Sep 30, 2031
- First posted
- Aug 13, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centre Hospitalier Intercommunal de Toulon La Seyne sur MerLead sponsor
- Groupe Français de Pneumo-CancérologieCollaborator
- University of LyonCollaborator
- Groupe Francais De Pneumo-CancerologieCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.